

Clinical and echocardiographic predictors of outcome in liver transplant patients

Irene Landi,¹ Suliman Alharbil,² Abdullah Alfehaid,² Sarah Aldosari,² Abdalla Eltayeb A.A,² Nadiyah Alruwaili,² Roberto Troisi,³ Domenico Galzerano,^{2,4} Mario Pirisi,¹ Olga Vrizz^{2,5}

¹Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy; ²Heart Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia; ³Complex Operating Unit of Hepato-Biliary-Pancreatic, Minimally Invasive and Robotic Surgery, Federico II University Hospital, Napoli, Italy; ⁴College of Medicine, Alfaisal University, Riyadh, Saudi Arabia; ⁵Department of Cardiology and Sport Medicine, San Antonio Hospital, San Daniele del Friuli, Udine, Italy

Correspondence: Olga Vrizz, Department of Cardiology and Sport Medicine, San Antonio Hospital, San Daniele del Friuli, Udine, Italy. E-mail: olgavriz@yahoo.com

Key words: liver transplant, heart function, liver cirrhosis, right ventricular dysfunction.

Contributions: all authors contributed to the study's conception and design. SALh, AA, SAId, AE, NA, RT, DG, material preparation, data collection and analysis; IL, OV, writing - first draft of the manuscript; MP, comments on previous versions of the manuscript.

Conflict of interest: the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Ethics approval and consent to participate: this study was approved by the Ethical Committee of King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia (protocol number 2191217).

Informed consent: written informed consent was obtained from a legally authorized representative for anonymized patient information to be published in this article. The manuscript does not contain any individual person's data in any form.

Patient consent for publication: written informed consent was obtained from a legally authorized representative for anonymized patient information to be published in this article. The manuscript does not contain any individual person's data in any form.

Availability of data and materials: the authors confirm that the data supporting the findings of this study are available within the article.

Funding: this research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Received: 21 February 2024.

Accepted: 9 April 2024.

Early view: 28 April 2024.

Publisher's note: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

©Copyright: the Author(s), 2024

Licensee PAGEPress, Italy

Monaldi Archives for Chest Disease 2025; 95:2963

doi: 10.4081/monaldi.2024.2963

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial International License (CC BY-NC 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Abstract

Liver transplant (LT) candidates undergo transthoracic echocardiography (TTE) before surgery to assess cardiac function and evaluate the echocardiographic probability of pulmonary hypertension (PHT). The improvement of pulmonary artery systolic pressure (PASP) after transplant is associated with higher survival rates in patients with mild or moderate PHT. Although studies analyze the outcomes of LT in patients treated for PHT, the prognostic value of PASP in patients without PHT in the follow-up is unknown. The aim of our study is to evaluate pre- and post-LT cardiac function, right ventricular function, pulmonary artery pressure, and their association with long-term mortality. 102 patients who underwent LT between 2011 and 2018 were compared for echocardiographic and hemodynamic parameters pre- and post-LT. After LT, systolic blood pressure, heart rate (HR), and PASP significantly increased, while tricuspid annular plane systolic excursion/PASP decreased. Moreover, the higher difference in HR and PASP between pre- and post-LT was highlighted in those patients who died during the follow-up period after LT. Among all the parameters tested, in the multivariable Cox regression for mortality, left ventricular ejection fraction and PASP difference were predictors of mortality. This study highlights the importance of TTE in LT screening as a tool to stratify patients at higher risk of death due to advanced cirrhotic cardiomyopathy and the importance of the change of echocardiographic parameters, in particular right and left ventricular hemodynamics, during the follow-up period. These parameters could be used to guide a more aggressive therapy.

Introduction

Cirrhosis-related cardiovascular abnormalities include decreased peripheral vascular resistance, decreased mean arterial pressure, and increased cardiac output (CO). Because of peripheral vasodilation, CO at rest is normal or increased. Nevertheless, echocardiography may reveal some abnormal diastolic and systolic parameters, a condition called "cirrhotic cardiomyopathy" [1]. An inflammatory phenotype characterizes the pathogenesis: endotoxemia stimulates cytokines and cardiodepressant mediators such as nitric oxide and endocannabinoids. In addition, cardiac dysfunction contributes to the pathogenesis of hepatorenal syndrome and increases cirrhotic patients' morbidity and mortality due to hemor-

rhage, infection, surgery, and liver transplantation (LT). Cirrhotic cardiomyopathy, manifesting as inadequate cardiac responsiveness to these challenges, underlies an increased fragility in end-stage liver patients, impacting the clinical course and outcomes during and after LT. Therefore, LT candidates typically undergo comprehensive transthoracic echocardiography (TTE) as part of the preoperative transplant work-up to assess cardiac function and to evaluate the echocardiographic probability of pulmonary hypertension (PHT) [2]. Notably, a mean pulmonary artery pressure (mPAP) of >50 mmHg at the time of LT had 100% perioperative mortality [3]. The improvement of systolic pulmonary artery systolic pressure (PASP) values after transplant surgery is associated with higher survival rates in patients with mild or moderate PHT. Although many studies analyze the outcomes of LT in patients treated for PHT with a $mPAP \geq 35$ mmHg, the prognostic value of systolic pulmonary pressure in patients without PHT in the long-term follow-up is unknown.

Our study aims to evaluate pre- and post-LT cardiac function, in particular right ventricle (RV) function and pulmonary artery pressure, and their association with long-term mortality.

Materials and Methods

Study population

A total of 102 patients who underwent LT between January 2011 and December 2018 and performed a pre- and post-LT TTE at least 6 months after surgery at King Faisal Specialist Hospital and Research Centre, Riyadh, KSA, were retrospectively identified. Exclusion criteria included patients who had low-quality TTE, missing pre- or post-TEE, and age younger than 18 years old.

All the candidates received a complete evaluation according to the standard protocol of the hospital, including complete history and comorbidities, physical examination [weight, systolic and diastolic blood pressure (SBP and DBP)], and blood analysis (red blood cell count, biochemistry, and coagulation parameters).

Demographic, clinical data, and outcome were collected from medical records. The main follow-up outcome measure was overall survival. Death occurrence and date were extracted from medical records when available. The overall survival was the main measure of mortality. The study was approved by the local Ethical Committee (REC number 2191217).

Echocardiographic evaluation

All patients underwent complete TTE performed by trained echocardiographers according to the international standards defined by the American Society of Echocardiography (ASE)/European Association of Cardiovascular Imaging (EACVI) [4,5]. All examinations were reviewed and analyzed by three certified experts in TTE (SA and AA) with an image processing workstation, Excelera, and Image Arena version 4.6 software (TomTec Imaging Systems, Unterschleissheim, Germany) for strain analysis (OV), blinded for patients' outcome. Each parameter was assessed in three to five consecutive cardiac cycles, and the mean values were used for data recording and analysis. For global longitudinal strain (GLS), endocardial borders were traced on the end-systolic frame in four-, two-, and three-chamber views, with end-systole defined by the QRS complex. The software (TomTec Imaging Systems, Unterschleissheim, Germany) tracks speckles along the endocardial border throughout the cardiac cycle. Peak longitudinal strain was computed automatically, generating regional data from six seg-

ments and an average value for each view, and then a final "Bull Eye" was generated.

Echocardiographic images of the RV focused apical four-chamber view were used for RV myocardial deformation parameters using the same software package mentioned above for GLS. After manual identification of the end-systolic RV endocardial border by three points (two on the tricuspid annulus and one at the RV apex), we calculated the RV free wall longitudinal strain (RVFWLS) value as recommended in the consensus document issued by the ASE/EACVI/Industry Task Force [6].

Additional measurements of the RV were considered, such as the RV basal diameter and right atrial volume. RV function was evaluated considering fractional area change (FAC) that was derived as [(RV diastolic area – RV systolic area) / RV diastolic area *100]. Pulsed tissue Doppler imaging (TDI) examination was performed to evaluate the longitudinal myocardial motion, placing a sample volume gate on the tricuspid annulus in the apical four-chamber view. Tricuspid annular plane systolic excursion (TAPSE), a parameter of global RV function which describes apex-to-base shortening, was obtained from the apical four-chamber view, placing the M-mode line at the lateral tricuspid valve annulus and measuring the height of the annulus movement during systole (normal values >17 mm according to the guidelines) [4]. The continuous wave Doppler of the tricuspid regurgitation (TR) trace was used to measure the difference in pressures between the RV and right atrium.

The simplified Bernoulli equation ($P = 4[TR_{max}]^2$) is used to calculate pressure difference using peak TR velocity; a value ≤ 2.8 m/s is considered normal. A coaxial TR jet is identified in the parasternal long axis (RV inflow), parasternal short axis, or apical four-chamber view. The peak velocity of the envelope is measured (TR_{max}), and the right atrial pressure (RAP) is assumed by the size and distensibility of the inferior vena cava during inspiration at rest and during forced inhalation, and this value is added to the peak TR velocity to obtain the PASP [7]. RV arterial coupling was evaluated using RVFWLS, TAPSE/PASP ratio, and RVFWLS/PASP ratio [8-10].

Statistical analysis

Variables were expressed as mean and standard deviation (SD). Clinical and TTE characteristics pre- and post-LT were calculated and compared using dependent Student's *t*-tests for pre- and post-LT. Independent Student's *t*-test or two-sample Wilcoxon rank-sum test to compare alive and deceased patients for continuous variables with normal distribution, and for not normal distributed variables were obtained. Univariate Cox regression analysis was used to select those variables statistically significant to be in the multivariate Cox regression analysis for overall survival. Hazard ratios and corresponding two-sided 95% confidence intervals were derived from the regression coefficients in the Cox models. The threshold of statistical significance was 0.05 for all tests used. Statistical analysis was performed using STATA version 16.

Results

A cohort of 102 patients (61 males, 59.8%, median age 59 years) who performed a TTE before and after LT in our hospital was identified. The main liver cirrhosis etiology was chronic viral hepatitis C (38,2%), followed by chronic viral hepatitis B (18,6%) (Table 1). The median time between the pre-LT TEE and

LT was 51 days, and the median time between the LT and the post-surgery TTE was 476 days. Follow-up time was 2171±1027 days (mean±SD). At the end of the follow-up, 76 patients (74.5%) were alive, 16 (15.7%) had died, and 10 (9.8%) were lost to follow-up (Table 1). Figure 1 presents the Kaplan-Meier survival curve for the population studied. Hemodynamic parameters pre- and post-LT are reported in Figure 2. Echocardiographic parameters pre- and post-LT are reported in Tables 2, and Table 3 shows the hemodynamic and echocardiographic differences between alive and deceased patients after LT. Left ventricular mass index and relative wall thickness increased, but the difference was not significant. Stroke volume, CO, and E/A ratio did not change significantly. Left ventricular ejection fraction (LVEF) decreased, but the difference was borderline significant. PASP increased significantly after LT, while TAPSE, right S' on TDI, longitudinal strain of the RV, TAPSE/PASP, and RVFWLS/PASP did not change significantly.

In univariable Cox regression analysis for mortality, hemodynamic parameters, cardiovascular risk factors, and echocardiographic parameters were tested. The statistically significant variables obtained were tested in the multivariable Cox regression analysis for mortality (Table 4). The increase in LVEF and PASP, expressed as the difference between post and pre-LT values, was associated with death.

Discussion

The main findings of our study are: i) all the hemodynamic parameters increased after LT, in particular SBP and heart rate (HR);

ii) a higher difference of HR between pre- and post-LT was highlighted in patients who did not survive; iii) there was a mild but significant increase in PASP after LT, although within the normal range, but in those who died the increase was above the limit of normality; and iv) the parameters that were significantly and independently associated with mortality were PASP and pre- and post-LVEF difference.

The present data supported the prognostic role of RV afterload in end-stage liver disease patients with RV function and pulmonary




Figure 1. The Kaplan-Meier survival curve of the liver transplant population studied.


Table 1. Baseline characteristics of the liver transplant population studied.

| | |
|---|---|
| Age, years (median) | 59 (54-65) |
| BMI (median), kg/m ² | 28.63 (24.69-31.57) |
| BSA (median), m ² | 1.77 (1.61-1.90) |
| Comorbidities, n (%) | Hypertension – 35 (24.6) Diabetes – 67 (66.2) CAD – 11 (10.9) |
| Indication to LT, n (%) | Chronic viral hepatitis C – 39 (38.2) Chronic viral hepatitis B – 19 (18.6) Autoimmune hepatitis – 13 (12.7) Cryptogenic liver cirrhosis – 12 (11.8) Non-alcoholic steatohepatitis – 12 (11.8) Schistosomiasis (Bilharziasis) – 3 Primary biliary cirrhosis – 2 Primary sclerosing cholangitis – 1 Liver infarction – 1 |
| Therapy at baseline evaluation, n (%) | Betablockers – 49 (48.5) Aspirin – 26 (25.5) ACE-I – 17 (16.8) ARB – 9 (8.8) Furosemide – 79 (78.2) Spironolactone – 65 (64.4) |
| Days between TTE and LT | 51 (26-161) |
| Days between LT and follow-up TTE | 476 (133-880) |
| Patients alive at the end of follow-up, n (%) | 76 (74.5) |
| Patients died at the end of follow-up, n (%) | 16 (15.7) |
| Patients lost at the follow-up, n (%) | 10 (9.8) |

Continuous variables are reported as median, and categorical variables are described as number of subjects (%). BMI, body mass index; BSA, body surface area; LT, liver transplant; CAD, coronary artery disease; INR, international normalized ratio; ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; TTE, transthoracic echocardiography.

pressure values within the normal limits before transplantation. End-stage liver disease is characterized by vascular changes such as splanchnic vasodilatation and increased blood flow, leading to hyperdynamic circulation and a slight increase in pulmonary pressures [11]. In addition, splanchnic collaterals caused smooth muscle hypertrophy and remodeling of the pulmonary vasculature, leading

to porto-PHT [12]. This hemodynamic state coexists with LV systolic and diastolic dysfunction, a condition called cirrhotic cardiomyopathy. The Cirrhotic Cardiomyopathy Consortium, established in 2018, revised the diagnostic criteria for cirrhotic cardiomyopathy following novel concepts and methods that have emerged in echocardiography over the last 15 years [13]. The proposed criteria



LT, liver transplant; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate.

Figure 2. Hemodynamic parameters pre- and post-liver transplant.

Table 2. Echocardiographic parameters pre- and post-liver transplant.

| Variables | Pre-LT (mean±SD) | Post-LT (mean±SD) | p |
|-------------------------------|------------------|-------------------|-------|
| Left ventricle | | | |
| LVM index (g/m ²) | 78.93±18.8 | 90.09±31.3 | 0.53 |
| RWT | 33.2±6.52 | 37.6±8.5 | 0.47 |
| LVEF (%) | 62.12±7.2 | 57.1±9.20 | 0.056 |
| CO (mL/min) | 5447.6±1714.14 | 5184.8±1525 | 0.32 |
| E/A | 1.23±0.57 | 0.94±0.62 | 0.63 |
| E/Em lat | 7.68±3.32 | 8.66±3.63 | 0.39 |
| LVGLS (%) | -21.5±4.17 | -17.57±3.62 | 0.89 |
| Right ventricle | | | |
| RVDA (cm ²) | 17.81±6.2 | 15.49±4 | 0.04 |
| RVSA (cm ²) | 8.47±2.49 | 7.98±2.47 | 0.09 |
| RV FAC (%) | 51.70±7.6 | 48.31±8.7 | 0.52 |
| TAPSE (mm) | 24.37±4.8 | 21.01±3.5 | 0.56 |
| PASP (mmHg) | 26.90±7.9 | 28.04±13.3 | 0.011 |
| TAPSE/PASP | 0.98±0.35 | 0.91±0.47 | 0.01 |
| RVFWLS (%) | -24.82±9.0 | -21.37±8.2 | 0.82 |
| RVFWLS/PASP | -0.98±0.52 | -0.87±0.53 | 0.12 |
| S' (mm) | 14.16±2.7 | 12.34±2.7 | 0.65 |

Left and right side morphological and functional features; p-value is calculated for the difference between pre-transplant and post-transplant values. LT, liver transplant; LVM, left ventricular mass; RWT, relative wall thickness; LVEF, left ventricular ejection fraction; SV, stroke volume; CO, cardiac output; LVGLS, left ventricular global longitudinal strain; E, early diastolic transmitral flow velocity; A, late (atrial) diastolic transmitral flow velocity; Em lat, early diastolic mitral annulus lateral velocity; RVDA, right ventricle diastolic area; RVSA, right ventricle systolic area; FAC, fractional area change; TAPSE, tricuspid annular plane excursion; PASP, Pulmonary artery systolic pressure; RVFWLS, right ventricle free wall longitudinal strain; S', tissue doppler imaging-derived tricuspid lateral annular systolic velocity.

rely on cardiac abnormalities identified by advanced ultrasonography, such as TDI and two-dimensional speckle-tracking echocardiography. When examined by 2-dimensional speckle-tracking echocardiography, patients with cirrhotic cardiomyopathy can show a reduction in GLS <18% or LVEF ≤50% on 2D echocardiography. Compared to systolic dysfunction, diastolic dysfunction is more common in this pathology, based on the new diagnostic criteria, which considers diastolic dysfunction when ≥3 of the following parameters are present: septal e' velocity <7 cm/s, E/e' ratio ≥15, LAVI >34 mL/m², TR velocity >2.8 m/s. In our study, LT candidates had normal pre- and post-LT EF and diastolic function parameters within the normal range or mildly abnormal, including the right heart function and PASP. Our data show that after transplantation, the hyperdynamic state improves as demonstrated by parameters such as LVEF, RV FAC, TAPSE, and RV systolic and diastolic area. On the other hand, a significant increase in PASP occurs following surgery, particularly in those who died. The LVEF did not change between pre- and post-transplant, nor did it increase in those who died. This observation may be explained by the fact that, even in cases where the hyperdynamic state has been resolved, a subset of patients continues to have both the LV hyperdynamic state and a negative pulmonary artery remodeling. At the time of transplantation, the clinical state associated with liver dysfunction in these patients was no longer reversible, and in the follow-up, it became a predictive factor for mortality. The results highlighted that even in the case of pulmonary pressure values within the normal limits or mildly increased, the non-invasive evaluation of PASP and EF by TTE can be a sensitive parameter to assess which patients are at

greater risk of negative outcomes after transplantation. A similar concept is expressed by increased HR. Increased resting HR due to hyperdynamic circulation is associated with all-cause mortality in LT recipients, as reported by Kwon *et al.* [14], demonstrating that patients with HR>80 beats/min had a significantly higher risk of death compared to patients with HR≤65 beats/min. RV-pulmonary artery (RV-PA) coupling refers to the relationship between RV contractility and RV afterload. A lower ratio indicates an inadequate RV contractile response to afterload variations. In this study, two parameters of RV-PA were used (TAPSE/PASP, RVFWS/PASP), but none of them were able to discriminate between those who survived from those who died. Most likely, in this population, the increase in PASP and its predictivity for mortality include other settings, and the RV function maintained a good adaptation to the increase in PASP. More frequent echocardiographic monitoring may be offered in patients with normal estimated lung pressures with higher differences between pre- and post-LT of PASP and LVEF values, and higher values after surgery might identify patients at higher risk of dying due to poor hemodynamic and circulatory adaptation.

This study had several limitations. First, it used a retrospective design in which no additional detailed workup was performed to identify other causes of PHT. Second, patients did not undergo right-heart catheterization. Instead, PASP was determined noninvasively using Doppler echocardiography, and considering the inaccuracies in RAP estimation, the latest ESC Pulmonary Hypertension Guidelines recommend the use of peak TRV instead of the estimated PAP as the variable for assigning the echocardiographic

Table 3. Two-sample Wilcoxon rank-sum test to compare hemodynamic and echocardiographic features between the alive and dead populations after liver transplant.

| | Pre-LT | | p | Post-LT | | p | Difference | | p |
|---------------------|------------|------------|-------|----------|-----------|-------|------------|----------|-------|
| | Alive | Dead | | Alive | Dead | | Alive | Dead | |
| SBP (mmHg) | 125.19±16 | 126.73±20 | 0.88 | 131.0±18 | 130.36±21 | 0.73 | 5.6±16 | 3.6±20 | 0.3 |
| DBP (mmHg) | 71.68±11 | 63±13 | 0.013 | 74.17±11 | 64.89±13 | 0.008 | 2.2±11 | 1.8±20 | 0.92 |
| HR (bpm) | 73.78±17 | 65.10±9 | 0.046 | 77.16±13 | 78.89±23 | 0.231 | 4.1±16 | 14.8±27 | 0.03 |
| Creatinine (mL/min) | 92.77±51 | 111±121 | 0.67 | 8.44±7.2 | 7.31±2.1 | 0.74 | -84±51 | -108±12 | 0.97 |
| LVEF (%) | 62.21±7.5 | 61.70±5.5 | 0.62 | 56.25±8 | 61.02±9.5 | 0.056 | -5.9±10 | -0.68±12 | 0.056 |
| TAPSE (mm) | 24±4.59 | 25.9±5.3 | 0.32 | 20.78±3 | 22.03±3 | 0.27 | -3.3±4.9 | -4.2±6.5 | 0.56 |
| PASP (mmHg) | 26.85±2.2 | 27.13±5.6 | 0.67 | 26.07±9 | 36.33±9 | 0.016 | -0.98±1 | 10.6±2 | 0.011 |
| RVFWS (%) | -24.79±9.3 | -24.93±7.5 | 0.92 | -21.28±8 | -21.78±6 | 0.12 | 3.28±1 | 3.14±7 | 0.82 |
| TAPSE/ PASP | 0.98±0.37 | 0.99±0.27 | 0.47 | 0.92±0.4 | 0.86±0.5 | 0.49 | -0.03±4 | -0.2±0.5 | 0.5 |
| RVFWS/PASP | -0.9±0.541 | -1.01±0.48 | 0.85 | -0.09±5 | -0.77±4 | 0.120 | 0.06±6 | 0.23±7 | 0.82 |

LT, liver transplant; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; LVEF, left ventricular ejection fraction; TAPSE, tricuspid annular plane excursion; PASP, pulmonary artery systolic pressure; RVFWS, right ventricle free wall longitudinal strain. The difference is the post-transplant value minus the pre-transplant value.

Table 4. Multivariable Cox regression for mortality in liver transplant.

| Variable | Hazard ratio | p | Confidence interval |
|------------------|--------------|-------|---------------------|
| DPB pre-LT | 0.950 | 0.052 | 0.902-1.000 |
| HR pre-LT | 0.967 | 0.174 | 0.922-1.014 |
| HR difference* | 1.022 | 0.260 | 0.983-1.062 |
| BMI pre-LT | 0.912 | 0.079 | 0.824-1.010 |
| LVEF difference* | 1.058 | 0.028 | 1.006-1.114 |
| PASP difference* | 1.042 | 0.014 | 1.000-1.078 |

LT, liver transplant; DPB, diastolic blood pressure; HR, heart rate; BMI, body mass index; LVEF, left ventricular ejection fraction; PASP, pulmonary artery systolic pressure; *difference is the post-transplant value minus the pre-transplant value.

graphic probability of PHT [15]. Catheterization may have elicited more accurate and additional data about pulmonary hemodynamics, such as pulmonary vascular resistance and CO. However, in most trials, PASP was obtained using Doppler echocardiography by the method used in our study, as the new guidelines have been published recently.

Conclusions

In conclusion, our data shows that: i) SBP and HR were higher after LT as well as PASP, although within normal limits; ii) in those patients who died after LT, PASP was significantly higher. This study highlights the importance of pre- and post-LT TTE screening as a tool to stratify patients at higher risk of death due to more advanced cirrhotic cardiomyopathy, indicated by increased PASP and a change in EF. These parameters could be used to guide a more aggressive therapy. More studies are required in light of new guidelines to assess the risk of increased pulmonary pressure and confirm the role of TTE as a non-invasive component essential for monitoring the risk of death in LT recipients.

References

1. Yoon KT, Liu H, Lee SS. Cirrhotic Cardiomyopathy. *Curr Gastroenterol Rep* 2020;22:45.
2. Myers RP, Lee SS. Cirrhotic cardiomyopathy and liver transplantation. *Liver Transpl* 2000;6:S44-52.
3. DuBrock HM, Runo JR, Sadd CJ, Burger CD, Cartin-Ceba R, Rosen CB, et al. Outcomes of liver transplantation in treated portopulmonary hypertension patients with a mean pulmonary arterial pressure ≥ 35 mmHg. *Transplant Direct* 2020;6:e630.
4. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging* 2015;16:233-70. Erratum in: *Eur Heart J Cardiovasc Imaging* 2016;17:412. Corrigendum in: *Eur Heart J Cardiovasc Imaging* 2016;17:969.
5. Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr* 2016;29:277-314.
6. Badano LP, Koliaas TJ, Muraru D, et al. Standardization of left atrial, right ventricular, and right atrial deformation imaging using two-dimensional speckle tracking echocardiography: a consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. *Eur Heart J Cardiovasc Imaging* 2018;19:591-600.
7. Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. *J Am Soc Echocardiogr* 2010;23:685-713.
8. Vrzi O, Pirisi M, Bossone E, et al. Right ventricular-pulmonary arterial uncoupling in mild-to-moderate systemic hypertension. *J Hypertens* 2020;38:274-81.
9. Vrzi O, Veldman G, Gargani L, et al. Age-changes in right ventricular function-pulmonary circulation coupling: from pediatric to adult stage in 1899 healthy subjects. The RIGHT Heart International NETwork (RIGHT-NET). *Int J Cardiovasc Imaging* 2021;37:3399-411.
10. Todaro MC, Carerj S, Zito C, et al. Echocardiographic evaluation of right ventricular-arterial coupling in pulmonary hypertension. *Am J Cardiovasc Dis* 2020;10:272-83.
11. Liberal R, Grant CR, Baptista R, Macedo G. Porto-pulmonary hypertension: a comprehensive review. *Clin Res Hepatol Gastroenterol* 2015;39:157-67.
12. Saleemi S. Portopulmonary hypertension. *Ann Thorac Med* 2010;5:5-9.
13. Izzy M, VanWagner LB, Lin G, et al. Redefining cirrhotic cardiomyopathy for the modern era. *Hepatology* 2020;71:334-45.
14. Kwon HM, Jun IG, Jung KW, et al. Pretransplant Resting heart rate and its association with all-cause mortality in liver transplant recipients. *Transplant Proc* 2017;49:1092-6.
15. Humbert M, Kovacs G, Hoeper MM, 2022 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG). *Eur Heart J* 2022; 43:3618-731.